SBIR Phase I: Supercritical Fluid Viral Inactivation in a Varying Potential Electrical Field

SBIR 第一阶段：变化电场中的超临界流体病毒灭活

• 批准号: 9660676
• 负责人: Trevor Castor
• 金额: $ 7.5万
• 依托单位: Aphios Corporation
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-01-01 至 1997-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=9660676&HistoricalAwards=false
• 关键词: SBIR; Phase; Supercritical; Fluid; Viral

A number of approaches have been employed for the inactivation or removal of viruses in therapeutic proteins derived from human plasma. These techniques are not always effective against a wide spectrum of human and animal viruses, are encumbered by process specific deficiencies, and often result in denaturation of the biologicals which they are designed to protect. Some of these methods are effective in inactivating enveloped viruses, such as HIV, but none are effective against non enveloped viruses such as HAV. Aphios has developed a rapid and generally applicable virus inactivation technique for both enveloped and non enveloped viruses based on supercritical fluid technology. In the proposed effort, we plan to enhance this technique by utilizing a constant, discharging or varying electrical field. The worldwide marketplace for human plasma and animal serum products is estimated to be S15 to S20 billion by the year 2000. The potential viral inactivation marketplace is estimated to be about 5% of this malt, approximately $0.7S to $1.0 billion. Combined demand for these therapeutics (fresh frozen plasma, fibrin glue, immunoglobulins) as well as transgenic proteins and recombinant therapeutics from mammalian cell culture will increase marketplace size and demand for cost efficient and generally applicable virus inactivation technology.

已经采用了许多方法来灭活或去除来源于人血浆的治疗性蛋白质中的病毒。这些技术并不总是对广谱的人类和动物病毒有效，受到工艺特异性缺陷的阻碍，并且经常导致它们旨在保护的生物制品变性。这些方法中的一些在灭活包膜病毒（例如HIV）方面是有效的，但没有一种对无包膜病毒（例如HAV）有效。Aphios开发了一种基于超临界流体技术的快速且普遍适用的包膜和非包膜病毒灭活技术。在提议的努力中，我们计划通过利用恒定的、放电的或变化的电场来增强这种技术。 到2000年，全球人血浆和动物血清产品的市场估计为150亿至200亿新元。据估计，潜在的病毒灭活市场约占该麦芽的5%，约为0.7亿至10亿美元。对这些治疗剂（新鲜冷冻血浆、纤维蛋白胶、免疫球蛋白）以及来自哺乳动物细胞培养物的转基因蛋白和重组治疗剂的组合需求将增加市场规模和对成本有效且普遍适用的病毒灭活技术的需求。